查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2108392

眼科藥品市場到2035年的分析和預測：按類型、產品類型、技術、應用、劑型、最終用戶、給藥途徑和開發階段分類

Ophthalmic Drugs Market Analysis and Forecast to 2035: Type, Product, Technology, Application, Form, End User, Mode, Stage
出版日期: | 出版商: Global Insight Services | 英文 350 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球眼科藥品市場預計將從2025年的411億美元成長到2035年的727億美元，CAGR為5.9%。眼科藥品市場成長的主要驅動力是全球眼科疾病和視力障礙盛行率的不斷上升。根據世界衛生組織（WHO）統計，全球至少有22億人患有近視或遠視，其中至少10億人是可以預防或未治療的。青光眼、白內障、糖尿病視網膜病變和乾眼症等疾病負擔的加重，以及對創新眼科治療投入的增加，推動先進眼科藥品的應用，並支撐著市場成長。

眼科藥品市場依類型可分為處方藥、非處方藥（OTC）、生技藥品製劑、生物相似藥和其他藥品。其中，處方藥因其廣泛用於治療青光眼、視網膜疾病和眼部發炎等慢性複雜性眼科疾病而佔據較大的市場佔有率。這些藥物需要醫生指導，並廣泛用於標靶治療。非處方藥的需求成長，尤其是在乾眼症和輕度眼部刺激等症狀方面，因為患者越來越傾向於方便的自我護理方案。生技藥品和生物相似藥正經歷快速成長，這得益於標靶治療和視網膜疾病治療的進步，以及昂貴的生物眼科藥物的低成本替代品的出現。眼科藥物遞送方法和個人化治療方案的持續創新，進一步推動了整個眼科藥品市場的成長。

市場區隔
類型 處方藥、非處方藥、生技藥品、生物相似藥、其他
產品 抗發炎藥物、抗感染藥、青光眼治療藥、抗過敏藥、視網膜疾病治療藥、乾眼症治療藥、其他
技術 小分子藥物、生技藥品、基因療法、奈米技術、其他
用途 青光眼、白內障、老齡化黃斑部病變（AMD）、糖尿病視網膜病變、乾眼症、葡萄膜炎、其他
形式 片劑、膠囊、眼藥水、軟膏、凝膠、注射、其他
最終用戶 醫院、眼科診所、門診手術中心、居家醫療、其他
給藥途徑 外用、口服、玻璃體內注射、眼眶周圍注射、其他
發展階段 藥物發現、臨床前研究、臨床試驗、法規核准、上市後監測及其他相關領域。

眼科藥品市場的適應症包括青光眼、白內障、老齡化黃斑部病變（AMD）、糖尿病視網膜病變、乾眼症和葡萄膜炎。由於眼壓升高盛行率不斷上升以及對降眼壓治療的需求日益成長，青光眼成為該市場的關鍵細分領域。老齡化黃斑部病變和糖尿病視網膜病變的市場規模正因全球人口老化和糖尿病發病率的上升而迅速擴大。由於螢幕使用時間增加、環境因素和生活方式的改變，乾眼症也日益受到重視。抗發炎療法、手術治療和標靶眼科藥物的進步，持續推動葡萄膜炎和白內障的治療市場成長。

區域概覽

到2025年，北美佔據全球眼科藥品市場最大的佔有率，這主要得益於其先進的醫療保健基礎設施、高發的老齡化性眼科疾病以及眾多著重眼科領域的領先企業的強大實力。該地區對青光眼、老齡化黃斑部病變（AMD）、糖尿病視網膜病變、乾眼症和視網膜疾病的治療需求日益成長。對眼科藥品研發的大量投資、生技藥品和緩釋給藥系統的廣泛應用以及有利的保險償付政策，都進一步加速了市場成長。此外，人們對眼科疾病早期診斷意識的提高、臨床試驗的擴展以及持續的產品創新，也進一步鞏固了北美在全球眼科藥品市場的主導地位。

由於人口老化加劇、糖尿病和視力相關疾病盛行率上升以及眼科醫療服務可及性的提高，亞太地區預計將成為眼科藥品市場成長最快的地區。隨著醫療基礎設施的不斷完善，中國、印度、日本、韓國和澳洲等國家對青光眼、白內障、糖尿病視網膜病變和乾眼症等疾病的治療需求日益成長。政府為預防失明而採取的措施、醫療保健支出的增加、眼科診所的擴建以及製藥公司對眼科治療投入的增加，都進一步推動了市場成長。此外，人們對預防性眼科保健意識的提高、先進藥物輸送技術的日益普及以及臨床研究活動的不斷拓展，預計將使亞太地區在預測期內成為成長最快的區域市場。

主要趨勢和促進因素

擴大先進眼科藥物傳遞系統的研發

眼科藥物市場正呈現強勁的發展趨勢，即致力於研發先進的眼內給藥系統，以提高治療效果和病患遵守用藥。製藥公司日益關注緩釋植入、奈米顆粒、眼內植入物和標靶給藥技術等創新，以克服傳統滴眼液吸收率低、需要頻繁給藥等難題。製劑技術的進步使得青光眼、視網膜疾病、乾眼症和其他眼科疾病的治療更有效。此外，生技藥品和基因療法在眼科疾病治療中的日益普及，也刺激了研發活動，推動了整個眼科藥物領域的創新。

眼科疾病率上升和全球老化問題日益嚴重。

眼科疾病盛行率的不斷上升和老年人口的快速成長是眼科藥品市場的主要促進因素。由於人口結構變化和糖尿病等慢性疾病發生率的上升，青光眼、白內障、老齡化黃斑部病變（AMD）、糖尿病視網膜病變和乾眼症等疾病的發生率日益增高。對有效預防視力障礙療法的需求不斷成長，推動了全球對眼科藥品的需求。此外，醫療保健支出的增加、眼科醫療服務可及性的提高以及製藥公司對創新眼科療法投入的增加，都促進了市場擴張。針對視網膜和退化性眼科疾病的標靶治療的研發也進一步加速了市場成長。

目錄

第1章 執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機會
  • 市場限制因素
  • 年複合成長率分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 處方藥
    • 非處方藥
    • 生技藥品
    • 生物相似藥
    • 其他
  • 市場規模及預測：依產品分類
    • 抗發炎藥
    • 抗感染藥物
    • 青光眼治療
    • 抗過敏藥物
    • 視網膜疾病的治療
    • 乾眼症治療
    • 其他
  • 市場規模及預測：依技術分類
    • 小分子藥物
    • 生技藥品
    • 基因治療
    • 奈米科技
    • 其他
  • 市場規模及預測：依應用領域分類
    • 青光眼
    • 白內障
    • 老齡化黃斑部病變（AMD）
    • 糖尿病視網膜病變
    • 乾眼症
    • 葡萄膜炎
    • 其他
  • 市場規模及預測：依類型
    • 片劑
    • 膠囊
    • 眼藥水
    • 軟膏
    • 凝膠
    • 注射藥物
    • 其他
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 眼科診所
    • 門診手術中心
    • 居家醫療
    • 其他
  • 市場規模及預測：依給藥途徑分類
    • 外用
    • 口服
    • 玻璃體內注射
    • 眼周給藥
    • 其他
  • 市場規模及預測：依發展階段分類
    • 藥物發現
    • 臨床前
    • 臨床試驗
    • 贊同
    • 上市後監測
    • 其他

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 其他亞太國家
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲國家

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 定價和成本利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要公司的策略

第8章 公司簡介

  • Novartis
  • Roche
  • Allergan
  • Bausch Health
  • Pfizer
  • Regeneron Pharmaceuticals
  • Bayer
  • Santen Pharmaceutical
  • Alcon
  • Sun Pharmaceutical
  • Teva Pharmaceutical
  • Aerie Pharmaceuticals
  • Otsuka Pharmaceutical
  • Nicox
  • Kala Pharmaceuticals
  • Ocular Therapeutix
  • Astellas Pharma
  • Hoya Corporation
  • Apellis Pharmaceuticals
  • Incyte Corporation

第9章 關於我們

簡介目錄
Product Code: GIS21358

The global Ophthalmic Drugs Market is projected to grow from $41.1 billion in 2025 to $72.7 billion by 2035, at a compound annual growth rate (CAGR) of 5.9%. The ophthalmic drugs market is supported by the rising prevalence of eye disorders and vision impairment worldwide. According to the World Health Organization (WHO), at least 2.2 billion people globally have a near or distance vision impairment, with at least 1 billion cases being preventable or untreated. The growing burden of conditions such as glaucoma, cataracts, diabetic retinopathy, and dry eye disease, coupled with increasing investments in innovative ophthalmic therapies, is driving the adoption of advanced ophthalmic drugs and supporting market growth.

The Type segment of the Ophthalmic Drugs Market includes prescription drugs, over-the-counter drugs, biologics, biosimilars, and others. Among these, prescription drugs hold a significant market share due to their extensive use in treating chronic and complex eye disorders such as glaucoma, retinal diseases, and ocular inflammation. These medications require medical supervision and are widely adopted for targeted therapeutic management. Over-the-counter drugs are gaining traction, particularly for conditions such as dry eye syndrome and minor ocular irritations, due to increasing patient preference for convenient self-care solutions. Biologics and biosimilars are witnessing rapid growth with advancements in targeted therapies, retinal disorder treatments, and cost-effective alternatives to expensive biologic ophthalmic medicines. Continuous innovation in ocular drug delivery and personalized treatment approaches is further supporting growth across ophthalmic drug categories.

Market Segmentation
TypePrescription Drugs, Over-the-Counter Drugs, Biologics, Biosimilars, Others
ProductAnti-inflammatory Drugs, Anti-infective Drugs, Anti-glaucoma Drugs, Anti-allergy Drugs, Retinal Disorder Drugs, Dry Eye Drugs, Others
TechnologySmall Molecule Drugs, Biopharmaceuticals, Gene Therapy, Nanotechnology, Others
ApplicationGlaucoma, Cataract, Age-related Macular Degeneration (AMD), Diabetic Retinopathy, Dry Eye Syndrome, Uveitis, Others
FormTablets, Capsules, Eye Drops, Ointments, Gels, Injections, Others
End UserHospitals, Ophthalmic Clinics, Ambulatory Surgical Centers, Homecare Settings, Others
ModeTopical, Oral, Intravitreal, Periocular, Others
StageDiscovery, Preclinical, Clinical Trials, Approval, Post-marketing Surveillance, Others

The Application segment of the Ophthalmic Drugs Market includes glaucoma, cataract, age-related macular degeneration (AMD), diabetic retinopathy, dry eye syndrome, uveitis, and others. Glaucoma represents a significant market segment due to the growing prevalence of elevated intraocular pressure and increasing demand for pressure-lowering therapies. Age-related macular degeneration and diabetic retinopathy are expanding rapidly with the rising aging population and increasing incidence of diabetes worldwide. Dry eye syndrome is also gaining importance due to increased screen exposure, environmental factors, and lifestyle changes. Uveitis and cataract treatments continue to contribute to market growth through advancements in anti-inflammatory therapies, surgical care, and targeted ocular medications.

Geographical Overview

North America held the largest share of the global ophthalmic drugs market in 2025, driven by its advanced healthcare infrastructure, high prevalence of age-related eye disorders, and strong presence of leading pharmaceutical companies specializing in ophthalmology. The region has witnessed increasing demand for therapies targeting glaucoma, age-related macular degeneration (AMD), diabetic retinopathy, dry eye disease, and retinal disorders. Significant investments in ophthalmic drug research, growing adoption of biologics and sustained-release drug delivery systems, and favorable reimbursement policies have further accelerated market growth. Additionally, increasing awareness of early eye disease diagnosis, expanding clinical trials, and continuous product innovation continue to reinforce North America's leadership in the global ophthalmic drugs market.

Asia Pacific is expected to register the highest growth in the ophthalmic drugs market due to its rapidly aging population, rising prevalence of diabetes and vision-related disorders, and improving access to eye care services. Countries such as China, India, Japan, South Korea, and Australia are witnessing growing demand for treatments for glaucoma, cataracts, diabetic retinopathy, and dry eye syndrome as healthcare infrastructure continues to improve. Government initiatives promoting blindness prevention, increasing healthcare expenditure, expanding ophthalmology clinics, and growing investments by pharmaceutical companies in ophthalmic therapeutics are further driving market growth. Moreover, rising awareness of preventive eye care, increasing adoption of advanced drug delivery technologies, and expanding clinical research activities are expected to position Asia Pacific as the fastest-growing regional market during the forecast period.

Key Trends and Drivers

Increasing Development of Advanced Ocular Drug Delivery Systems:

The Ophthalmic Drugs Market is witnessing a strong trend toward the development of advanced ocular drug delivery systems designed to improve therapeutic effectiveness and patient compliance. Pharmaceutical companies are increasingly focusing on innovations such as sustained-release implants, nanoparticles, ocular inserts, and targeted delivery technologies to overcome challenges associated with conventional eye drops, including poor absorption and frequent dosing requirements. Advances in formulation technologies are enabling more effective treatments for glaucoma, retinal disorders, dry eye disease, and other ophthalmic conditions. Additionally, the growing adoption of biologics and gene-based therapies for eye diseases is expanding research and development activities, driving innovation across the ophthalmic pharmaceutical landscape.

Rising Prevalence of Eye Disorders and Aging Global Population:

The increasing prevalence of eye disorders, along with the rapid growth of the aging population, is a major driver of the Ophthalmic Drugs Market. Conditions such as glaucoma, cataracts, age-related macular degeneration (AMD), diabetic retinopathy, and dry eye syndrome are becoming more common due to demographic changes and rising incidences of chronic diseases such as diabetes. The growing need for effective treatments to prevent vision impairment is increasing demand for ophthalmic medications worldwide. Furthermore, rising healthcare expenditure, improved access to eye care services, and increasing investments by pharmaceutical companies in innovative ophthalmic therapies are supporting market expansion. The development of targeted treatments for retinal and degenerative eye diseases is further accelerating market growth.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by Form
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Mode
  • 2.8 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Prescription Drugs
    • 4.1.2 Over-the-Counter Drugs
    • 4.1.3 Biologics
    • 4.1.4 Biosimilars
    • 4.1.5 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Anti-inflammatory Drugs
    • 4.2.2 Anti-infective Drugs
    • 4.2.3 Anti-glaucoma Drugs
    • 4.2.4 Anti-allergy Drugs
    • 4.2.5 Retinal Disorder Drugs
    • 4.2.6 Dry Eye Drugs
    • 4.2.7 Others
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Small Molecule Drugs
    • 4.3.2 Biopharmaceuticals
    • 4.3.3 Gene Therapy
    • 4.3.4 Nanotechnology
    • 4.3.5 Others
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Glaucoma
    • 4.4.2 Cataract
    • 4.4.3 Age-related Macular Degeneration (AMD)
    • 4.4.4 Diabetic Retinopathy
    • 4.4.5 Dry Eye Syndrome
    • 4.4.6 Uveitis
    • 4.4.7 Others
  • 4.5 Market Size & Forecast by Form (2020-2035)
    • 4.5.1 Tablets
    • 4.5.2 Capsules
    • 4.5.3 Eye Drops
    • 4.5.4 Ointments
    • 4.5.5 Gels
    • 4.5.6 Injections
    • 4.5.7 Others
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Ophthalmic Clinics
    • 4.6.3 Ambulatory Surgical Centers
    • 4.6.4 Homecare Settings
    • 4.6.5 Others
  • 4.7 Market Size & Forecast by Mode (2020-2035)
    • 4.7.1 Topical
    • 4.7.2 Oral
    • 4.7.3 Intravitreal
    • 4.7.4 Periocular
    • 4.7.5 Others
  • 4.8 Market Size & Forecast by Stage (2020-2035)
    • 4.8.1 Discovery
    • 4.8.2 Preclinical
    • 4.8.3 Clinical Trials
    • 4.8.4 Approval
    • 4.8.5 Post-marketing Surveillance
    • 4.8.6 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 Form
      • 5.2.1.6 End User
      • 5.2.1.7 Mode
      • 5.2.1.8 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 Form
      • 5.2.2.6 End User
      • 5.2.2.7 Mode
      • 5.2.2.8 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 Form
      • 5.2.3.6 End User
      • 5.2.3.7 Mode
      • 5.2.3.8 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 Form
      • 5.3.1.6 End User
      • 5.3.1.7 Mode
      • 5.3.1.8 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 Form
      • 5.3.2.6 End User
      • 5.3.2.7 Mode
      • 5.3.2.8 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 Form
      • 5.3.3.6 End User
      • 5.3.3.7 Mode
      • 5.3.3.8 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 Form
      • 5.4.1.6 End User
      • 5.4.1.7 Mode
      • 5.4.1.8 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 Form
      • 5.4.2.6 End User
      • 5.4.2.7 Mode
      • 5.4.2.8 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 Form
      • 5.4.3.6 End User
      • 5.4.3.7 Mode
      • 5.4.3.8 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 Form
      • 5.4.4.6 End User
      • 5.4.4.7 Mode
      • 5.4.4.8 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 Form
      • 5.4.5.6 End User
      • 5.4.5.7 Mode
      • 5.4.5.8 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 Form
      • 5.4.6.6 End User
      • 5.4.6.7 Mode
      • 5.4.6.8 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 Form
      • 5.4.7.6 End User
      • 5.4.7.7 Mode
      • 5.4.7.8 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 Form
      • 5.5.1.6 End User
      • 5.5.1.7 Mode
      • 5.5.1.8 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 Form
      • 5.5.2.6 End User
      • 5.5.2.7 Mode
      • 5.5.2.8 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 Form
      • 5.5.3.6 End User
      • 5.5.3.7 Mode
      • 5.5.3.8 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 Form
      • 5.5.4.6 End User
      • 5.5.4.7 Mode
      • 5.5.4.8 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 Form
      • 5.5.5.6 End User
      • 5.5.5.7 Mode
      • 5.5.5.8 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 Form
      • 5.5.6.6 End User
      • 5.5.6.7 Mode
      • 5.5.6.8 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 Form
      • 5.6.1.6 End User
      • 5.6.1.7 Mode
      • 5.6.1.8 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 Form
      • 5.6.2.6 End User
      • 5.6.2.7 Mode
      • 5.6.2.8 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 Form
      • 5.6.3.6 End User
      • 5.6.3.7 Mode
      • 5.6.3.8 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 Form
      • 5.6.4.6 End User
      • 5.6.4.7 Mode
      • 5.6.4.8 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 Form
      • 5.6.5.6 End User
      • 5.6.5.7 Mode
      • 5.6.5.8 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Novartis
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Roche
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Allergan
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Bausch Health
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Pfizer
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Regeneron Pharmaceuticals
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Bayer
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Santen Pharmaceutical
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Alcon
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Sun Pharmaceutical
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Teva Pharmaceutical
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Aerie Pharmaceuticals
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Otsuka Pharmaceutical
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Nicox
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Kala Pharmaceuticals
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Ocular Therapeutix
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Astellas Pharma
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Hoya Corporation
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Apellis Pharmaceuticals
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Incyte Corporation
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us